DOI QR코드

DOI QR Code

miR-485 Acts as a Tumor Suppressor by Inhibiting Cell Growth and Migration in Breast Carcinoma T47D Cells

  • Anaya-Ruiz, Maricruz (Laboratory of Cellular Biology, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social) ;
  • Bandala, Cindy (Department of Research Support, Instituto Nacional de Rehabilitacion) ;
  • Perez-Santos, Jose Luis Martin (Vice-rectory of Research and Postgraduate Studies, Benemerita Universidad Autonoma de Puebla)
  • Published : 2013.06.30

Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs (18-25 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. In this context, the present study aimed to evaluate the in vitro effects of miR-485 mimics in breast carcinoma T47D cells. Forty-eight hours after T47D cells were transfected with miR-485 mimics, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects on cell viability. Colony formation and cell migration assays were adopted to determine whether miR-485 affects the proliferation rates and cell migration of breast carcinoma T47D cells. Our results showed that ectopic expression of miR-485 resulted in a significant decrease in cell growth, cell colony formation, and cell migration. These findings suggest that miR-485 might play an important role in breast cancer by suppressing cell proliferation and migration.

Keywords

Breast cancer;microRNA;migration;tumor suppressor

References

  1. Costa FF, Jared M, Bischof JM, et al (2011). Identification of MicroRNAs as potential prognostic markers in ependymoma. PLoS One, 6, 25114. https://doi.org/10.1371/journal.pone.0025114
  2. Fils-Aime N, Dai M, Guo J, et al (2013). MicroRNA-584 and the Protein Phosphatase and Actin Regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-$\beta$ mediates the migration and actin dynamics of breast cancer cells. J Biol Chem, 288, 11807-23. https://doi.org/10.1074/jbc.M112.430934
  3. Haghighat S, Akbari M, Ghaffari S (2012). Standardized breast cancer mortality rate compared to the general female population of Iran. Asian Pac J Cancer Prev, 13, 5525-8. https://doi.org/10.7314/APJCP.2012.13.11.5525
  4. Harquail J, Benzina S, Robichaud GA (2012). MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark, 11, 269-80.
  5. Hu X, Guo J, Zheng L, et al (2013). The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Molec Cancer Res, 11, 240-50. https://doi.org/10.1158/1541-7786.MCR-12-0432
  6. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, et al (2012). miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumours. EMBO Mol Med, 4, 1214-29. https://doi.org/10.1002/emmm.201201483
  7. Chen CF, He X, Arslan AD, et al (2011). Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase $II\alpha$ and drug responsiveness. Mol Pharmacol, 79, 735-41. https://doi.org/10.1124/mol.110.069633
  8. Imam JS, Plyler JR, Bansal H, et al (2012). Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One, 7, 52397. https://doi.org/10.1371/journal.pone.0052397
  9. Kala R, Peek GW, Hardy TM, et al (2013). MicroRNAs: an emerging science in cancer epigenetics. J Clin Bioinform, 16, 6-13.
  10. Kim TH, Kim YK, Kwon Y, et al (2010). Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology, 57, 734-43. https://doi.org/10.1111/j.1365-2559.2010.03686.x
  11. Lages E, Ipas H, Guttin A, et al (2012). MicroRNAs: molecular features and role in cancer. Front Biosci, 17, 2508-40. https://doi.org/10.2741/4068
  12. Lee S, and Vasudevan S (2013). Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol, 768, 97-126. https://doi.org/10.1007/978-1-4614-5107-5_7
  13. Li S, Meng H, Zhou F, et al (2013). MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract, 209, 179-83. https://doi.org/10.1016/j.prp.2012.12.002
  14. Lodes MJ, Caraballo M, Suciu D, et al (2009). Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray. PLoS One, 4, 6229. https://doi.org/10.1371/journal.pone.0006229
  15. Parpart S, Wang XW (2013). microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep, 1, 71-9. https://doi.org/10.1007/s40139-012-0002-7
  16. Selcuklu SD, Donoghue MT, Rehmet K, et al (2012). MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem, 287, 29516-28. https://doi.org/10.1074/jbc.M111.335943
  17. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  18. Singh R, Mo YY (2013). Role of microRNAs in breast cancer. Cancer Biol Ther, 14, 201-12. https://doi.org/10.4161/cbt.23296
  19. Tang J, Ahmad A, Sarkar FH (2012). The role of MicroRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci, 13, 13414-37. https://doi.org/10.3390/ijms131013414
  20. Wang QY, Tang J, Zhou CX, et al (2012). The down-regulation of miR-129 in breast cancer and its effect on breast cancer migration and motility. Sheng Li Xue Bao, 64, 403-11.
  21. Yang H, Cho ME, Li TWH, et al (2013). MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest. 123, 285-298. https://doi.org/10.1172/JCI63861
  22. Yang L, Sun TT, Wang N (2012). The incidence and mortality trends of female breast cancer in Beijing, China: between 2004 and 2008. Zhonghua Yu Fang Yi Xue Za Zhi, 46, 1009-14.
  23. Zhou J, Tian Y, Li J, et al (2013). miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun, 433, 207-12. https://doi.org/10.1016/j.bbrc.2013.02.084

Cited by

  1. Analysis of the microRNA expression profile of normal human dermal papilla cells treated with 5α-dihydrotestosterone vol.12, pp.1, 2012, https://doi.org/10.3892/mmr.2015.3478
  2. Role of MicroRNAs in the Warburg Effect and Mitochondrial Metabolism in Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7015
  3. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs vol.31, pp.6, 2014, https://doi.org/10.1007/s10585-014-9664-3
  4. An investigation into anti-proliferative effects of microRNAs encoded by the miR-106a-363 cluster on human carcinoma cells and keratinocytes using microarray profiling of miRNA transcriptomes vol.5, pp.1664-8021, 2014, https://doi.org/10.3389/fgene.2014.00246
  5. miR-485-5p inhibits bladder cancer metastasis by targeting HMGA2 vol.36, pp.4, 2015, https://doi.org/10.3892/ijmm.2015.2302
  6. UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-4917-1
  7. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression vol.7, pp.3, 2016, https://doi.org/10.1038/cddis.2016.27
  8. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma vol.12, pp.9, 2017, https://doi.org/10.1371/journal.pone.0184969
  9. MicroRNA-485 inhibits malignant biological behaviour of glioblastoma cells by directly targeting PAK4 vol.51, pp.5, 2017, https://doi.org/10.3892/ijo.2017.4122
  10. Developments in oligometastatic hormone-sensitive prostate cancer pp.1433-8726, 2018, https://doi.org/10.1007/s00345-018-2542-x
  11. The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3 vol.233, pp.9, 2018, https://doi.org/10.1002/jcp.26371